Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy

被引：84

作者：

Routy, Jean-Pierre ^{[1
,2
,3
]}

Boulassel, Mohamed-Rachid ^{[2
]}

Yassine-Diab, Bader ^{[3
,4
,5
]}

Nicolette, Charles ^{[6
]}

Healey, Don ^{[6
]}

Jain, Renu ^{[6
]}

Landry, Claire ^{[4
,5
]}

Yegorov, Oleg ^{[3
,4
,5
]}

Tcherepanova, Irina ^{[6
]}

Monesmith, Tamara ^{[6
]}

Finke, Lothar ^{[6
]}

Sekaly, Rafick-Pierre ^{[3
,4
,5
]}

机构：

[1] McGill Univ, McGill Univ Hlth Ctr, Immunodeficiency Serv, Montreal, PQ, Canada

[2] McGill Univ, McGill Univ Hlth Ctr, Div Hematol, Montreal, PQ, Canada

[3] CHU Montreal, Ctr Rech, INSERM, U743, Montreal, PQ H2X 1P1, Canada

[4] CHU Montreal, Hop St Luc, Ctr Rech, Lab Immunol, Montreal, PQ H2X 1P1, Canada

[5] Natl Immune Monitoring Lab, Montreal, PQ, Canada

[6] Argos Therapeut Inc, Durham, NC USA

来源：

CLINICAL IMMUNOLOGY | 2010年 / 134卷 / 02期

基金：

美国国家卫生研究院;

关键词：

HIV; Immunotherapy; Vaccine; Dendritic cells; Acquired immunodeficiency syndrome; TREATMENT INTERRUPTION; VIRUS; CTL; VACCINE; IMMUNOTHERAPY; IMMUNIZATION; MATURATION; INFECTION; VIREMIA; VPR;

D O I：

10.1016/j.clim.2009.09.009

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immunogenicity, manufacturing feasibility, and safety of a novel, autologous dendritic cell (DC)-based immunotherapy (AGS-004) was evaluated in ten human immunodeficiency virus type 1 (HIV-1)-infected adults successfully treated with antiretroviral therapy (ART). Personalized AGS-004 was produced from autologous monocyte-derived DCs electroporated with RNA encoding CD40L and HIV antigens (Gag, Vpr, Rev, and Nef) derived from each subjects' pre-ART plasma. Patients received monthly injections of AGS-004 in combination with ART. AGS-004 was produced within a mean of 6 weeks and yielded 4-12 doses/subject Full or partial HIV-specific proliferative immune responses occurred in 7 of 9 evaluable subjects. Responses were specific for the AGS-004 presented HIV antigens and preferentially targeted CD8(+) T cells. Mild adverse events included flu-like symptoms, fatigue, and injection site reactions. No evidence of autoimmunity, changes in viral load, or significant changes in absolute CD4(+) and CD8(+) T cell counts were observed. This pilot study supports the further clinical investigation of AGS-004. (C) 2009 Elsevier Inc. All rights reserved.

引用

页码：140 / 147

页数：8

共 39 条

[31] The Immunosuppressive Properties of the HIV Vpr Protein Are Linked to a Single Highly Conserved Residue, R90 [J].